| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b4c92bd22b33daf54ff54c309f9a1863 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-23 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56911
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1221 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 |
| filingDate |
2020-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08b73c1958e9d65b7a6c1bcd4ad90b60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82d9f66122c021964a02b34a5fe92436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba3712d0bb1b250a582a4a48d35633c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5255d7e2e58e31e283dce91306aa1609
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3c320c7cc0f6bd33178dd24bca865d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32aa99fec897f6efb29fcbea2557959c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b10fe7f5fe8f6d73f5e9b444824dd9d7 |
| publicationDate |
2022-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113913389-A |
| titleOfInvention |
Hybridoma cell strain, monoclonal antibody of Brucella-resistant BAB antigen, and preparation and application thereof |
| abstract |
The invention belongs to the technical field of genetic engineering, and particularly relates to a hybridoma cell strain, a Brucella-resistant BAB antigen monoclonal antibody, and preparation and application thereof. The invention aims at the preparation and screening of the BAB antigen with good reactogenicity to obtain the hybridoma cell strain, and prepares the monoclonal antibody of the Brucella-resistant BAB antigen, thereby providing a foundation for Brucella diagnosis and development of novel vaccines. |
| priorityDate |
2020-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |